Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 12HER2-positive Breast Cancer 6Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Salivary Gland Neoplasms 1Rare Tumor 1Lung Neoplasms 1Locally Advanced Breast Cancer 1HER2-positive Metastatic Breast Cancer 1HER2-positive Early Breast Cancer 1HER2-positive Advanced Breast Cancer 1HER2-expressing Advanced Solid Tumors 1HER2 Positive Breast Cancer 1HER2 Insertion Mutation Positive Advanced NSCLC 1Esophageal Squamous Cell Carcinoma 1Breast Neoplasm Female 1Breast Cancer Metastatic 1Breast Cancer Invasive 1Breast Cancer Female 1Advanced Breast Cancer 1

Interventions

pyrotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × HER2 Insertion Mutation Positive Advanced NSCLC × pyrotinib × Clear all
NCT04144569 2024-09-19

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

Hunan Province Tumor Hospital

Phase 2 Recruiting
30 enrolled
Thoracic

HER2 Insertion Mutation Positive Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡